In this regard, one interesting example is represented by ML385, a small molecule inhibitor, which was found to suppress NRF2-MAF binding and to chemosensitize NSCLC cells in vitro as well as in NSCLC animal models, in the context of KEAP1 inactivation [119]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.